Fluphenazine
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Fluphenazine: From Schizophrenia to Manic Bipolar Affective Disorder
Note on indication selection: This Evidence Pack lists ten TxGNN-ranked candidate indications for fluphenazine (ranks #1–#9 by raw score: retinal dystrophy, syndromic/X-linked myopia subtypes, hydranencephaly, a glycosylation disorder, Charcot-Marie-Tooth disease, a cortical malformation syndrome, and glycine encephalopathy). The pack’s own
repurposing_rationalefields flag every one of these as having no known mechanistic link to fluphenazine’s pharmacology and zero supporting trials or literature — consistent withevidence_level: L5andrecommendation: Holdfor all nine. These appear to be knowledge-graph artefacts rather than genuine repurposing signals, so leading with them would be misleading. The tenth-ranked candidate, manic bipolar affective disorder, is the only one with a coherent mechanistic rationale, real-world literature, and an evidence-supportedL3 / Proceed with Guardrailsscoring — this report focuses on that candidate.
One-Sentence Summary
Fluphenazine is a first-generation (typical) phenothiazine antipsychotic, established for schizophrenia and related psychoses. The TxGNN model — supported by clinical literature rather than raw prediction score alone — points to manic episodes in bipolar affective disorder as a mechanistically plausible and already partially evidenced extension of use, with 20 supporting publications but no registered clinical trials identified in this pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in the supplied UK licence data (schizophrenia and other psychoses is the established indication for this phenothiazine antipsychotic) |
| Predicted New Indication | Manic Bipolar Affective Disorder |
| TxGNN Prediction Score | 99.98% (rank 647 of the model’s overall output, but the most evidence-supported candidate among those returned) |
| Evidence Level | L3 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data was not available in the structured dataset (flagged as a data gap: DG002). Based on established pharmacological knowledge, fluphenazine is a phenothiazine-class typical antipsychotic that acts principally as a dopamine D2 receptor antagonist, with additional antagonism at D1, α1-adrenergic and H1-histaminergic receptors.
Acute mania in bipolar affective disorder is associated with mesolimbic dopaminergic hyperactivity, which is the same pathway targeted by D2-antagonist antipsychotics. Other typical and atypical antipsychotics sharing this mechanism — haloperidol, chlorpromazine, risperidone — are already established treatments for acute mania, and long-acting injectable (LAI) formulations (including fluphenazine decanoate) are used off-label in bipolar maintenance to improve adherence. This makes the fluphenazine-to-bipolar-mania signal a within-class extrapolation from proven pharmacology, rather than a novel, unsupported hypothesis — which distinguishes it clearly from the other nine candidates in this pack.
Two of the retrieved publications describe fluphenazine specifically in bipolar disorder (a case series on off-label use in comorbid substance abuse, and a case report of neuroleptic malignant syndrome during fluphenazine decanoate maintenance), while the remainder address the broader LAI-antipsychotic class in bipolar mania, lending indirect but consistent support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26243837 | 2015 | Systematic Review + Expert Consensus | Clin Psychopharmacol Neurosci | Systematic review and expert consensus supporting LAI antipsychotics, including fluphenazine decanoate, for maintenance treatment of bipolar disorder |
| 39756485 | 2025 | Retrospective Cohort | J Affective Disorders | Addition of LAI antipsychotics during manic episodes was associated with reduced rehospitalisation in bipolar disorder |
| 22494448 | 2012 | Review | CNS Drugs | Reviews efficacy/safety of first- and second-generation depot antipsychotics for bipolar maintenance treatment |
| 30129771 | 2018 | Comparative Effectiveness Study | J Comp Eff Res | LAI antipsychotic initiation associated with lower hospitalisation risk in bipolar I disorder |
| 36779113 | 2023 | Case Report | Cureus | Off-label fluphenazine used to manage bipolar disorder with comorbid substance abuse; described as effective with community-based monitoring |
| 34353834 | 2021 | Case Report | BMJ Case Reports | Neuroleptic malignant syndrome occurring in a bipolar disorder patient maintained on fluphenazine decanoate depot — safety signal |
| 37345508 | 2023 | Review | Expert Opin Pharmacother | Practical guidance on switching to/from LAI antipsychotics, relevant to fluphenazine depot use in severe mental illness |
| 28112539 | 2017 | Review | J Child Adolesc Psychopharmacol | Reviews LAI antipsychotic use in children and adolescents, limited evidence base |
| 27028966 | 2016 | Review/Case Series | J Child Adolesc Psychopharmacol | Case series on LAI antipsychotic efficacy in adolescents |
| 20851282 | 2010 | Case Report | Gen Hosp Psychiatry | Case report of antipsychotic-induced stuttering, noting fluphenazine among agents previously implicated |
UK Market Information
Fluphenazine currently holds no active UK marketing authorisations in this dataset (market status: not marketed). No licence records were available to summarise product names, dosage forms or approved indication text.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
One literature-derived signal worth noting: a 2021 case report (34353834) described neuroleptic malignant syndrome in a bipolar disorder patient on fluphenazine decanoate depot — this is consistent with the known class risk of NMS with typical antipsychotics and should be factored into any monitoring plan.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale is strong (established D2-antagonist class effect in mania) and is supported by observational cohort data and expert consensus on LAI antipsychotics — including fluphenazine specifically — in bipolar disorder. However, no registered clinical trials, no UK marketing authorisation, and no structured safety/DDI data were available, so this cannot proceed without further work.
To proceed, the following is needed:
- Formal safety review via SmPC/BNF and Yellow Card data, since structured warnings, contraindications and DDI data were not available (DG001)
- Confirmation of mechanism of action from DrugBank or equivalent primary source (DG002)
- A pathway to UK marketing authorisation or specials/import route, given the drug is not currently marketed in the UK
- Consideration of a prospective or registry-based study, since existing evidence is observational/case-level rather than trial-based
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.